Publication | Open Access

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

OncologyPancreatic CancerGastrointestinal OncologyGemcitabine Versus GemcitabineClinical TrialsPhase Ii/iiiPharmacotherapyMetastatic Pancreatic CancerCancer TreatmentMedicineRadiation OncologyHealth Sciences